The Era of Small-Molecule GLP-1 Drugs Is Emerging The approval of Orforglipron represents more than the launch of a new drugit reflects a major shift in oral GLP-1 drug development trends toward small-molecule innovation
Kakuda, Michael Biermer Clinical Pharmacology in Drug Development .2023
Studies have demonstrated a PFS benefit for patients who receive the combination of nivolumab and the antilymphocyte-activation gene-3 (LAG-3) antibody relatlimab, compared with nivolumab monotherapy.[25] OS and response rate data are immature
Secondly, our study did not investigate the nutritional supplements, dietary status, as well as intake of lipid-lowering drugs (e.g
[49] observed significant reduction in hs-CRP with twice-daily exenatide, and DURATION-2, DURATION-3, DURATION-3 extension, and DURATION-5 studies observed considerable reductions in inflammatory markers such as hs-CRP or CRP (Table 2) [484950515253545556575859606162636465666768697071727374757677787980818283848586]